San Clemente-based Cameron Health Inc., which is being bought by Boston Scientific Corp., said today that its implantable heart defibrillator was proven safe and effective in a 330-person clinical trial.
Boston Scientific, of Natick, Mass., agreed to buy Cameron in March in a deal that could be worth up to $1.35 billion, depending on several regulatory milestones.
Cameron presented results of its study at the Heart Rhythm Society’s Annual Scientific sessions in Boston.
The company’s device is distinguished by its lack of intravenous electric lead wires to transmit electricity to the heart. Lead wires can often cause serious patient complications.
Last month, a Food and Drug Administration advisory panel said Cameron’s defibrillator’s benefits outweighed its risks. The FDA generally follows its panels’ advice when it comes to medical device approvals.
